Condition
Renal Transplant Recipient
Total Trials
5
Recruiting
0
Active
1
Completed
3
Success Rate
75.0%-12% vs avg
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
75.0%
-11.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
75% success
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (2)
Trial Status
Completed3
Terminated1
Active Not Recruiting1
Trial Success Rate
75.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT03504241Phase 1Completed
Tolerance by Engaging Antigen During Cellular Homeostasis
NCT04955366Phase 2Active Not RecruitingPrimary
Abatacept Conversion in Kidney Transplantation
NCT02064699TerminatedPrimary
Assessing the Risk of CMV Infection of the Renal Transplant About R + by Cellular Immunity Analyzed by the QuantiFERON ®-CMV Test.
NCT04979754Completed
REnal TRansplant Outcomes After CARdiac Surgery (RETROCAR)
NCT04169698Phase 2Completed
Alendronate Versus Denosumab in Kidney Transplant Patients
Showing all 5 trials